4D Molecular Therapeutics, Inc. (FDMT) stock
FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/302% above fair value
$12.12−0.88 (-6.74%)
Close on Nov 12, 2026Market cap $874.46MP/E –Yield –
4D Molecular Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
4D Molecular Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -208.6%. For fiscal 2025 it was -164.4%, against -434778.4% the year before. The highest annual figure on record is -164.4% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -164.4% | +434613.9 |
| FY2024 | Dec 31, 2024 | -434778.4% | −434291.8 |
| FY2023 | Dec 31, 2023 | -486.6% | +2948.8 |
| FY2022 | Dec 31, 2022 | -3435.4% | −3040.0 |
| FY2021 | Dec 31, 2021 | -395.4% | +21.1 |
| FY2020 | Dec 31, 2020 | -416.5% | +289.3 |
| FY2019 | Dec 31, 2019 | -705.8% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -1883.1% | +61312.4 |
| Q2 FY2026 | Jun 30, 2026 | -1929.0% | +362457.7 |
| Q1 FY2026 | Mar 31, 2026 | -2256.6% | +340400.5 |
| Q4 FY2025 | Dec 31, 2025 | 22.8% | +4967122.8 |
| Q3 FY2025 | Sep 30, 2025 | -63195.6% | +1398237.8 |
| Q2 FY2025 | Jun 30, 2025 | -364386.7% | +334673.3 |
| Q1 FY2025 | Mar 31, 2025 | -342657.1% | −226939.3 |
| Q4 FY2024 | Dec 31, 2024 | -4967100.0% | −4967049.2 |
| Q3 FY2024 | Sep 30, 2024 | -1461433.3% | −1449041.7 |
| Q2 FY2024 | Jun 30, 2024 | -699060.0% | −689435.2 |
| Q1 FY2024 | Mar 31, 2024 | -115717.9% | −113522.3 |
| Q3 FY2023 | Sep 30, 2023 | -50.8% | +5087.4 |
| Q2 FY2023 | Jun 30, 2023 | -12391.6% | +4945.4 |
| Q1 FY2023 | Mar 31, 2023 | -9624.8% | −7464.2 |
| Q4 FY2022 | Dec 31, 2022 | -2195.6% | +25068.5 |
| Q3 FY2022 | Sep 30, 2022 | -5138.2% | −3510.2 |
| Q2 FY2022 | Jun 30, 2022 | -17337.0% | −17285.0 |
| Q1 FY2022 | Mar 31, 2022 | -2160.6% | −1340.3 |
| Q4 FY2021 | Dec 31, 2021 | -27264.1% | −27158.6 |
| Q3 FY2021 | Sep 30, 2021 | -1628.0% | −1210.9 |
| Q2 FY2021 | Jun 30, 2021 | -52.1% | +320.2 |
| Q1 FY2021 | Mar 31, 2021 | -820.3% | – |
| Q3 FY2020 | Sep 30, 2020 | -105.6% | – |
| Q2 FY2020 | Jun 30, 2020 | -417.1% | – |
| Q1 FY2020 | Mar 31, 2020 | -372.3% | – |
See a number that looks wrong?